Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced an investor event scheduled for October 9, 2024, at 10:00 a.m. EDT in Waltham, Mass. The event will focus on reviewing the company's orexin portfolio and development strategy. It will feature presentations by Alkermes' Research & Development team, followed by a clinician and thought leader panel discussion and a Q&A session.

The event will be accessible virtually via webcast, with registration available on the Investors section of Alkermes' website. A replay will be archived for 30 days following the presentation. Alkermes is a global biopharmaceutical company specializing in neuroscience, with a portfolio of commercial products for various mental health conditions and a pipeline of candidates for neurological disorders, including narcolepsy.

News Market Reaction – ALKS

-3.43%

-3.43% Session move

In the trading session that priced this news, ALKS declined 3.43%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel discussion. A question and answer session will follow the presentations.

The event will also be available virtually via webcast. Registration for the webcast is available on the Investors section of the company's website at www.alkermes.com. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start. A replay of the webcast will be archived on the Investors section of the company's website at www.alkermes.com for 30 days following the presentation.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-host-investor-event-to-review-orexin-portfolio-strategy-302257677.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) hosting its investor event to review its orexin portfolio strategy?

Alkermes (ALKS) is hosting its investor event on Wednesday, October 9, 2024, starting at 10:00 a.m. EDT in Waltham, Mass.

What will be discussed at Alkermes' (ALKS) upcoming investor event?

The event will focus on reviewing Alkermes' orexin portfolio and development strategy, featuring presentations by the Research & Development team, a clinician and thought leader panel discussion, and a Q&A session.

How can investors access Alkermes' (ALKS) October 9, 2024 investor event?

Investors can access the event virtually via webcast. Registration is available on the Investors section of Alkermes' website at www.alkermes.com.

What therapeutic areas does Alkermes (ALKS) focus on?

Alkermes focuses on neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and a pipeline for neurological disorders, including narcolepsy.